The dose of paclitaxel used in the new approach was 16-fold lower than that typically used in free paclitaxel, but with similar efficacy.

The FDA granted an orphan drug designation to PEP-010 for the treatment of patients with metastatic pancreatic cancer.

Microplastics have been found almost everywhere that scientists have looked for them. Now, according to research published in the ACS partner journal Environment & Health, these bits of plastic — from ...

It's been a rough week for Seahawks fans. After expected releases early in the week of overpaid veterans, news of 10-year veteran wide receiver Tyler Lockett's release was announced by the team.

Entyvio’s dosage is an intravenous (IV) infusion every 8 weeks or a subcutaneous injection every 2 weeks. The starting dosage is two infusions 2 weeks apart. After that, you’ll continue with ...

– Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected in Q2 2025 – – VCN-01 development bolstered by ...

The Company is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered ...

The federal government will spend $20 million to expand the only local manufacturing facility of IV fluids. Production of the medicine is expected to jump from 60 million units a year to 80 ...

When Brian DeDecker drives past the bucolic green soybean fields en route to his childhood home in rural Illinois, his mind drifts not to the past but to the future. As a first-generation college ...

1Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. 2Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical ...

BASKING RIDGE, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata” or the "Company”), a clinical-stage pharmaceutical company developing innovative therapies for ...